ArticleScientific reports2025
Data-driven analysis of the relationship between the HbA1c/HDL-C ratio and coronary artery calcification: a cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Data-driven glycolipid network phenotypes reveal a graded risk spectrum for cardiometabolic multimorbidity: a prospective study in middle-aged and older Chinese adults.Lipids in health and disease · 2026Article
- HbA1c-to-HDL-C ratio and risk of incident cardiovascular disease among older adults: evidence from a 7-year prospective cohort study in southwestern China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Coronary artery calcification (CAC) is a well-established cardiovascular disease (CVD) pathogenesis marker closely associated with dysregulated glucose and lipid metabolism. The present study investigated the relationship between the glycated hemoglobin A1c (HbA1c)/high-density lipoprotein cholesterol (HDL-C) ratio and CAC. A total of 1608 eligible participants were enrolled in the study. The HbA1c/HDL-C ratio was calculated by dividing HbA1c by HDL-C. LASSO regression, logistic regression, and receiver operating characteristic curve (ROC) analysis were performed to examine the relationship between the HbA1c/HDL-C ratio and CAC. The nomogram incorporating the HbA1c/HDL-C ratio was further established by multivariate logistic regression and evaluated. The HbA1c/HDL-C ratios in the CAC group were significantly higher than the control group [4.73 (4.01, 5.56) vs. 4.34 (3.67, 5.05), p < 0.001]. Subjects with an elevated HbA1c/HDL-C ratio (≥ 4.99) exhibited a higher prevalence of CAC [146/486 (30.04) vs. 200/1122 (17.83), p < 0.001]. Furthermore, an elevated HbA1c/HDL-C ratio was an independent effect factor for CAC [odds ratio, 1.135; 95% confidence interval (CI), 1.008-1.279; p = 0.037]. The area under the ROC curve of the HbA1c/HDL-C ratio was 0.630 (95% CI 0.596-0.663), and the model incorporating age, gender, body mass index, hypertension, diabetes mellitus, and the HbA1c/HDL-C ratio was 0.718 (95% CI 0.686-0.751). The constructed nomogram based on this model demonstrated favorable discrimination and clinical utility. In conclusion, the HbA1c/HDL-C ratio is closely associated with CAC and is an independent factor for CAC in asymptomatic adults without CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.